Literature DB >> 25530926

Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells.

Adrian Smedowski1, Jussi J Paterno2, Elisa Toropainen3, Debasish Sinha4, Edward Wylegala5, Kai Kaarniranta2.   

Abstract

Various preservative-free eye drop formulations for glaucoma treatment have been marketed intending to decrease ocular surface side effects and improve tolerability. However, preservative-free eye drops including different solubilizers to dissolve the antiglaucoma drugs may induce detrimental effects in the eye. In this study, we exposed human corneal epithelial cells (HCE-2) for 1, 6, 12, 24 and 48 hours to the first preservative-free (PF) tafluprost (Taflotan®), the recently-launched preservative-free (PF) latanoprost (Monoprost®), preservative benzalkonium chloride (BAK) and the excipient macrogolglycerol hydroxystearate 40 (MGHS40) using dilutions 0.1%, 0.3%, 1.0%, 3.0% and 10.0% of the original products. The cells also were exposed to undiluted PF tafluprost and PF latanoprost once a day for 9 days. Cellular morphology was examined by light microscopy and cell proliferation by Ki-67 fluorescent staining with cell viability being determined by erythrosine staining and the release of lactate dehydrogenase (LDH). Mitochondrial metabolic activity was evaluated with the colorimetric MTT assay. The secretion of interleukin 6 (IL-6) was measured with ELISA. HCE-2 cells displayed no significant morphological changes after PF tafluprost treatment, but PF latanoprost caused clear cell loss. Moreover, PF latanoprost, BAK and MGHS40 evoked cellular damage and inflammation with increasing concentrations and time. Furthermore, undiluted daily PF latanoprost application significantly increased LDH release and IL-6 secretion as compared to PF tafluprost. MGHS40 was observed to be associated with the toxicity of PF latanoprost. Excipients in ocular drops should receive more attention in the future, since they seem to trigger similar detrimental effects in cells as preservatives.

Entities:  

Keywords:  cornea; cytotoxicity; drug; excipient; glaucoma; inflammation; preservative

Year:  2014        PMID: 25530926      PMCID: PMC4270205     

Source DB:  PubMed          Journal:  J Biochem Pharmacol Res


  38 in total

1.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

2.  In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination.

Authors:  Françoise Brignole-Baudouin; Luisa Riancho; Hong Liang; Zaki Nakib; Christophe Baudouin
Journal:  J Ocul Pharmacol Ther       Date:  2011-03-16       Impact factor: 2.671

3.  A critical appraisal and comparison of the quality and recommendations of glaucoma clinical practice guidelines.

Authors:  Yvonne Ou; Ivan Goldberg; Clive Migdal; Paul P Lee
Journal:  Ophthalmology       Date:  2011-04-20       Impact factor: 12.079

4.  A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.

Authors:  Richard K Parrish; Paul Palmberg; Wang-Pui Sheu
Journal:  Am J Ophthalmol       Date:  2003-05       Impact factor: 5.258

5.  Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.

Authors:  M De Saint Jean; F Brignole; A F Bringuier; A Bauchet; G Feldmann; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

6.  Influence of artificial tears on corneal epithelium in dry-eye syndrome.

Authors:  M Göbbels; M Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

Review 7.  Update on prostaglandin analogs.

Authors:  Camille Hylton; Alan L Robin
Journal:  Curr Opin Ophthalmol       Date:  2003-04       Impact factor: 3.761

8.  Corneal and conjunctival changes caused by commonly used glaucoma medications.

Authors:  Robert J Noecker; Lisa A Herrygers; Raana Anwaruddin
Journal:  Cornea       Date:  2004-07       Impact factor: 2.651

9.  Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system.

Authors:  Hong Liang; Aude Pauly; Luisa Riancho; Christophe Baudouin; Françoise Brignole-Baudouin
Journal:  Br J Ophthalmol       Date:  2011-03-22       Impact factor: 4.638

10.  Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial.

Authors:  Douglas G Day; Thomas R Walters; Gail F Schwartz; Thomas K Mundorf; Charlie Liu; Rhett M Schiffman; Marina Bejanian
Journal:  Br J Ophthalmol       Date:  2013-06-06       Impact factor: 4.638

View more
  5 in total

Review 1.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

2.  FluoroGold-Labeled Organotypic Retinal Explant Culture for Neurotoxicity Screening Studies.

Authors:  Adrian Smedowski; Marita Pietrucha-Dutczak; Ruchi Maniar; Michael Ajeleti; Iwona Matuszek; Joanna Lewin-Kowalik
Journal:  Oxid Med Cell Longev       Date:  2018-02-13       Impact factor: 6.543

3.  SCD1-Fatty Acid Desaturase Inhibitor MF-438 Alleviates Latent Inflammation Induced by Preservative-Free Prostaglandin Analog Eye Drops.

Authors:  Anna Pacwa; Joanna Machowicz; Alicja Wojtyniak; Marita Pietrucha-Dutczak; Elisa Toropainen; Ali Koskela; Ewa Mrukwa-Kominek; Joanna Lewin-Kowalik; Adrian Smedowski
Journal:  J Inflamm Res       Date:  2022-02-08

4.  Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.

Authors:  Yoshihiko Esaki; Atsushi Shimazaki; Pertti Pellinen
Journal:  Open Ophthalmol J       Date:  2016-05-31

5.  Comparison of the Efficacy of Fluorometholone With and Without Benzalkonium Chloride in Ocular Surface Disease.

Authors:  Yeoun-Hee Kim; Jae-Chang Jung; Soon-Young Jung; Sung Yu; Kyoo Won Lee; Young Jeung Park
Journal:  Cornea       Date:  2016-02       Impact factor: 2.651

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.